Reviews/Intermittent Fasting and Time Restricted Eating/Time-restricted eating feasible with no serious adverse events
Saf · IFTRE-SAF-01 · v2
Across seven primary studies in people with obesity, type 2 diabetes, healthy adults, and older adults, time-restricted eating was consistently described as something people could stick to, and none of the trials reported serious harms. Several trials state plainly that no serious adverse events occurred [2][7][15], the largest and longest trial found no meaningful difference in adverse events between groups [1], and participants kept to their eating windows most days of the week [2][8][11][15]. The panel judged the evidence strong in direction: feasibility and the absence of reported serious harms recur across independent trials. What it could not firmly establish is that adherence is uniformly 'high' rather than moderate, since compliance varied widely and was often recorded by participants themselves [3][11]. The trials were also small and mostly short, so rare or long-term harms could simply not have had the chance to show up. That mix of consistent direction but soft magnitude and thin long-term data is why the panel stopped short of its top tier.
Seven primary studies converge on time-restricted eating being feasible and free of reported serious adverse events [2][7][8][11][15]. Adherence was moderate-to-high: 6.1 of 7 days per week in [2], a mean of 84% of days in [8], 72% of days in [11], 79% in [15], and 4.7 to 5.4 days per week in [3]. The largest randomised trial retained 84.9% of participants over 12 months and found no substantial between-group difference in adverse events [1]. 'No serious adverse events were reported' appears verbatim in [2], [7], and [15], and [8] reported only 'few reported adverse events'. The contested point: The evidence and the panel divide on the word 'high': the Synthesist read adherence as moderate-to-high and well-supported, while the Sceptic held it to be moderate and variable, pointing to 72% compliance with a 4 to 100% range in [11]. The second fault line is whether absence of reported serious harm in small (N=10 to 139), mostly short trials is evidence of safety at all.
All 15 papers behind this claim with their DOIs and what each does to it, the panel’s arbitration, the evidence gap map and the open research questions. Free, and sent to your inbox.
We’ll also send you other claims from Intermittent Fasting and Time Restricted Eating, one at a time, and tell you when a release or a pivotal trial changes a grade. Unsubscribe by replying.
One reviewer's only job is to attack the finding. The challenges below were weighed before the grade was set.
The 'no serious adverse events' clause rests on small (N=10-139), mostly short trials that are underpowered to detect rare serious harms; absence of reported events is not evidence of safety.
'High adherence' is undefined and not uniformly met — [11] reports 72% compliance with a 4-100% range and [3] 67-77% of days — so adherence is moderate and variable, not uniformly high.
Where it remains uncertain. Adherence is variable and often self-reported ([11] compliance 72% with a 4 to 100% range; [3] 4.7 to 5.4 days per week), and the trials are small and mostly 4 to 12 weeks, so 'high' adherence and long-term safety are not firmly established.
Aleatory
Serious adverse events are rare enough that cohorts of N=10 to 139 [8][1] may contain none by chance, so their absence is partly a matter of sampling.
Epistemic
Most trials run 4 to 12 weeks; only [1] and [2] reach 6 to 12 months, so harms or feasibility decay beyond a year are simply not measured.
Inferential
No trial sets a threshold for 'high' adherence, so classifying 72% [11] or 4.7 to 5.4 days per week [3] as high is a judgement, not a measured fact.
The load-bearing papers from a corpus of 15, each classified by what it does to the claim. Every DOI is taken from the corpus the claim was graded on.
No excess adverse events over 12 months in the largest RCT.
“there were no substantial differences between the groups in the numbers of adverse events”
Panel auditInternal validity: high · scope of inference: Adults with obesity following 8-hour TRE plus calorie restriction over 12 months.Key limitations: no serious-AE count · no eating-window adherence reported · AE statement is comparative only
High adherence (6.1/7 days) in a randomised T2D trial.
“No serious adverse events were reported.”
Panel auditInternal validity: high · scope of inference: Adults with obesity and type 2 diabetes on 8-hour TRE over 6 months.Key limitations: small sample (75) · 6-month follow-up · adherence self-defined via eating window
Feasibility of TRE support in obesity+hypertension.
“A bidirectional texting strategy was feasible for helping patients with obesity and hypertension initiate and adhere to time-restricted eating.”
Panel auditInternal validity: medium · scope of inference: Adults with obesity and hypertension in cardiology clinics attempting TRE with texting support.Key limitations: small, underpowered · self-reported adherence · no serious-AE reporting
3 of 15 papers shown. The full review lists all of them, with the panel’s arbitration →
Claims are graded at each quarterly release, and re-graded between releases only when a pivotal trial lands. Every change is a new version of the claim.
Converging primary evidence supports feasibility and absence of reported serious adverse events, but small, short, self-report-dependent trials and a variable adherence picture keep this at Likely rather than Established.
Release 2026-q4 re-graded every claim from its corpus under protocol v0.19. An earlier release's grade is shown for the record; it came from an earlier protocol and is not a movement.
Assumptions that carry weight but are not themselves established.
The panel records the gap that would most move the claim, and the study that would close it.
Power to detect rare serious harms. Every included trial is N=10 to 139 and mostly short, so a genuinely rare serious adverse event could not surface; the 'no serious adverse events' clause rests on this limitation. The panel rates this the highest-importance open gap for the claim, and names the study design that would close it: A large, adequately powered, longer-duration randomised trial or pooled safety analysis with prospective adverse-event ascertainment.
Open question: At what rate do serious adverse events occur under daily-window time-restricted eating when the sample is large enough to detect them? Why it is still open: All included trials are small (N=10 to 139) and report absence, not quantified risk, so the true serious-event rate is unknown.
Priors is a sceptical first reader, not peer review, and not medical advice.
Release 2026-q4 · graded 21 Oct 2026 · protocol v0.19